ATE443259T1 - Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests - Google Patents

Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Info

Publication number
ATE443259T1
ATE443259T1 AT02761799T AT02761799T ATE443259T1 AT E443259 T1 ATE443259 T1 AT E443259T1 AT 02761799 T AT02761799 T AT 02761799T AT 02761799 T AT02761799 T AT 02761799T AT E443259 T1 ATE443259 T1 AT E443259T1
Authority
AT
Austria
Prior art keywords
circulative
antigens
antigen
determination
therapeutic antibodies
Prior art date
Application number
AT02761799T
Other languages
English (en)
Inventor
Maher Albitar
Michael Keating
Taghi Manshouri
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Application granted granted Critical
Publication of ATE443259T1 publication Critical patent/ATE443259T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/807—Apparatus included in process claim, e.g. physical support structures
    • Y10S436/809—Multifield plates or multicontainer arrays
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/107497—Preparation composition [e.g., lysing or precipitation, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
AT02761799T 2001-09-20 2002-09-20 Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests ATE443259T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32367901P 2001-09-20 2001-09-20
PCT/US2002/030142 WO2003024993A2 (en) 2001-09-20 2002-09-20 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays

Publications (1)

Publication Number Publication Date
ATE443259T1 true ATE443259T1 (de) 2009-10-15

Family

ID=23260258

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02761799T ATE443259T1 (de) 2001-09-20 2002-09-20 Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Country Status (7)

Country Link
US (10) US7718387B2 (de)
EP (2) EP1438583B1 (de)
JP (4) JP4424987B2 (de)
AT (1) ATE443259T1 (de)
AU (1) AU2002327037A1 (de)
DE (1) DE60233744D1 (de)
WO (1) WO2003024993A2 (de)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6762032B1 (en) * 1999-08-23 2004-07-13 Biocrystal, Ltd. Compositions, assay kits, and methods for use related to a disease condition comprising multiple sclerosis and/or a pro-MS immune response
AU2048501A (en) * 2000-02-16 2001-08-27 Genentech Inc. Uses of agonists and antagonists to modulate activity of tnf-related molecules
CA2453995A1 (en) * 2001-08-03 2003-02-20 Genentech, Inc. Tacis and br3 polypeptides and uses thereof
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests
US20050043516A1 (en) * 2002-07-25 2005-02-24 Genentech, Inc. TACI antibodies and uses thereof
EP1944320A1 (de) * 2002-12-16 2008-07-16 Genentech, Inc. Immunglobulinvarianten und Verwendungen davon
PT2272868E (pt) * 2003-06-05 2015-07-07 Genentech Inc Terapêutica de combinação para distúrbios de células b
US20050163775A1 (en) * 2003-06-05 2005-07-28 Genentech, Inc. Combination therapy for B cell disorders
CA2532556A1 (en) * 2003-07-29 2005-02-24 Genentech, Inc. Assay for human anti cd20 antibodies and uses therefor
BRPI0412629A (pt) * 2003-08-29 2006-09-26 Genentech Inc método de tratamento de disfunção ocular em mamìferos
US20050069958A1 (en) * 2003-09-26 2005-03-31 Mills Rhonda A. Method for simultaneous evaluation of a sample containing a cellular target and a soluble analyte
US20090226397A1 (en) * 2003-10-24 2009-09-10 Nora Therapeutics, Inc. Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination
EP2198876B1 (de) * 2003-10-24 2012-12-05 Nora Therapeutics, Inc. Verfahren zur Reduzierung der Wahrscheinlichkeit des Implantationsversagens bei einer Person
US8338373B2 (en) * 2003-10-24 2012-12-25 Nora Therapeutics, Inc. Method for reducing the risk of spontaneous abortion in a human female subject
WO2005045058A2 (en) * 2003-10-27 2005-05-19 Monogram Biosciences, Inc. Detecting human anti-therapeutic antibodies
US20050186206A1 (en) * 2003-12-19 2005-08-25 Genentech, Inc. Detection of CD20 in therapy of autoimmune diseases
KR20060107555A (ko) * 2003-12-19 2006-10-13 제넨테크, 인크. 이식 거부에서 ｃｄ20의 검출
EP1773393A2 (de) * 2004-05-05 2007-04-18 Genentech, Inc. Verhütung von autoimmunerkrankungen mittels anti-cd20-antikörper
CA2568336A1 (en) * 2004-06-04 2005-12-22 Genentech, Inc. Method for treating lupus
EP1753455A2 (de) 2004-06-04 2007-02-21 Genentech, Inc. Verfahren zur behandlung von multipler sklerose
JP2008507555A (ja) * 2004-07-22 2008-03-13 ジェネンテック・インコーポレーテッド シェーグレン症候群の治療方法
US20060024744A1 (en) * 2004-07-28 2006-02-02 Mills Rhonda A Methods for substantially simultaneous evaluation of a sample containing a cellular target and a soluble analyte
RU2411956C2 (ru) * 2004-10-05 2011-02-20 Дженентек, Инк. Способ лечения васкулита
EP1645284A1 (de) * 2004-10-08 2006-04-12 Charité - Universitätsmedizin Berlin Verwendung von CDw52-Liganden zur Behandlung von Erkrankungen, die auf degenerierten Makrophagen basieren
ATE503187T1 (de) * 2004-12-23 2011-04-15 Hoffmann La Roche Nachweis eines therapeutischen antikörpers in einem versuchstier
GT200600020A (es) * 2005-01-13 2006-11-08 Procedimiento de tratamiento
DOP2006000029A (es) * 2005-02-07 2006-08-15 Genentech Inc Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
TW200714289A (en) * 2005-02-28 2007-04-16 Genentech Inc Treatment of bone disorders
AR053579A1 (es) * 2005-04-15 2007-05-09 Genentech Inc Tratamiento de la enfermedad inflamatoria intestinal (eii)
ZA200709956B (en) * 2005-05-20 2009-02-25 Genentech Inc Pretreatment of a biological sample from an autoimmune disease subject
US20070009976A1 (en) * 2005-07-06 2007-01-11 Helmut Lenz Detection of a target antigen irrespective of the presence or absence of a corresponding therapeutic antibody
US20070042443A1 (en) 2005-08-17 2007-02-22 Quest Diagnostics Investments Incorporated Hematopoietic cell phenotyping using free circulating cellular markers
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US9726673B2 (en) * 2005-11-23 2017-08-08 Genentech, Inc. Methods and compositions related to B cell assays
AR056857A1 (es) * 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
DE102006012613B4 (de) * 2006-03-17 2010-01-14 Mpb Meltec Patent- Und Beteiligungsgesellschaft Mbh Verfahren zur Bestimmung der therapeutischen Wirksamkeit von Substanzen
TW200817680A (en) * 2006-06-02 2008-04-16 Glaxosmithkline Biolog Sa Method
EP2067044B1 (de) * 2006-09-12 2013-07-03 F. Hoffmann-La Roche AG Assay für antikörper gegen arzneistoff
WO2008036374A2 (en) * 2006-09-21 2008-03-27 Medistem Laboratories, Inc. Allogeneic stem cell transplants in non-conditioned recipients
HUE037162T2 (hu) 2007-07-09 2018-08-28 Genentech Inc Diszulfidkötés redukciójának megelõzése polipeptidek rekombináns elõállítása során
WO2009052293A1 (en) 2007-10-16 2009-04-23 Zymogenetics, Inc. Combination of blys inhibition and anti-cd 20 agents for treatment of autoimmune disease
US20110311448A1 (en) * 2007-11-02 2011-12-22 Ann Marie Schmidt Antibody to rage and uses for in vivo imaging or for targeting therapy
CN101952725B (zh) 2007-12-03 2014-12-10 多摩川精机株式会社 使用了包覆磁性微粒的生物传感方法以及用于该方法的生物传感装置
US7914785B2 (en) 2008-01-02 2011-03-29 Bergen Teknologieverforing As B-cell depleting agents, like anti-CD20 antibodies or fragments thereof for the treatment of chronic fatigue syndrome
EP2077281A1 (de) 2008-01-02 2009-07-08 Bergen Teknologioverforing AS Anti-CD20-Antikörper oder Fragmente davon zur Behandlung von chronischen Ermüdungssyndrom
US11051733B2 (en) * 2008-01-18 2021-07-06 Wake Forest University Health Sciences Isolating and purifying cells for therapy
TW201438738A (zh) 2008-09-16 2014-10-16 建南德克公司 治療進展型多發性硬化症之方法
WO2010075249A2 (en) 2008-12-22 2010-07-01 Genentech, Inc. A method for treating rheumatoid arthritis with b-cell antagonists
US20110142836A1 (en) * 2009-01-02 2011-06-16 Olav Mella B-cell depleting agents for the treatment of chronic fatigue syndrome
WO2011019619A1 (en) 2009-08-11 2011-02-17 Genentech, Inc. Production of proteins in glutamine-free cell culture media
BR112012012160B1 (pt) 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
US20110195397A1 (en) * 2010-02-10 2011-08-11 Selinfreund Richard H Drink mixture for the stabilization of diagnostic biomarkers
WO2012022682A1 (en) 2010-08-17 2012-02-23 F. Hoffmann-La Roche Ag Anti-human igg1 antibody
EP2710377B8 (de) * 2011-05-19 2015-10-28 Baxalta Incorporated Nachweis von zirkulierenden adamts13-antikörperkomplexen
EP3511717A3 (de) 2011-09-29 2019-09-25 Meso Scale Technologies, LLC. Biodosimetriepaneele und verfahren
CN103930123B (zh) 2011-11-15 2016-11-09 沃尔特及伊莱萨霍尔医学研究院 可溶性介体
EP2676966A1 (de) * 2012-06-19 2013-12-25 Biouniversa S.r.l. BAG3 als biochemisches Serum und Gewebemarker
BR112015000665A2 (pt) 2012-07-13 2017-06-27 Hoffmann La Roche método para a determinação da quantidade de um anticorpo
CA2878814C (en) * 2012-08-17 2023-03-14 Morphosys Ag Complex-specific antibodies and antibody fragments and its use
AU2013344807B2 (en) * 2012-11-15 2018-05-24 The Walter And Eliza Hall Institute Of Medical Research Soluble mediator
US20150293086A1 (en) * 2014-04-14 2015-10-15 Abreos Biosciences, Inc. Lateral flow immunoassay
CN104360057B (zh) * 2014-10-22 2016-10-05 上海泰因生物技术有限公司 一种检测抗cd52抗体的elisa反应体系与方法
JP6407694B2 (ja) * 2014-12-16 2018-10-17 株式会社日立ハイテクノロジーズ プラズマ処理装置
ES2911415T3 (es) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Métodos y kits
WO2016198833A2 (en) 2015-06-08 2016-12-15 Arquer Diagnostics Limited Methods
CR20210429A (es) 2015-06-24 2021-09-24 Hoffmann La Roche ANTICUERPOS ANTI-RECEPTOR DE TRANSFERRINA CON AFINIDAD DISEÑADA (Divisional 2017-0562)
CN104965076B (zh) * 2015-07-14 2017-01-18 上海拜豪生物科技有限公司 一种镉螯合型免疫复合物及其制备方法和应用
TWI819458B (zh) 2015-10-02 2023-10-21 瑞士商赫孚孟拉羅股份公司 雙特異性抗‐人類cd20/人類轉鐵蛋白受體抗體及使用方法
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
CN114891102A (zh) 2015-10-29 2022-08-12 豪夫迈·罗氏有限公司 抗变体Fc区抗体及使用方法
US11027021B2 (en) 2016-03-15 2021-06-08 Seagen Inc. Combinations of PBD-based antibody drug conjugates with Bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
EP3469001A4 (de) 2016-06-09 2020-05-06 Seattle Genetics, Inc. Kombinationen von pbd-basierten antikörper-arzneimittel-konjugaten mit flt3-inhibitoren
USD800912S1 (en) 2016-06-17 2017-10-24 Abreos Biosciences, Inc. Point-of-care diagnostic device
WO2018031887A1 (en) 2016-08-12 2018-02-15 Abreos Biosciences, Inc. Detection and quantification of natalizumab
US11365454B2 (en) 2017-09-26 2022-06-21 Poet Research, Inc. Systems and methods for processing lignocellulosic biomass
BR112021003016A2 (pt) 2018-08-31 2021-05-18 Alector Llc anticorpos isolados, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir um anticorpo e para prevenir, reduzir o risco ou tratar uma doença e composição farmacêutica
JP7678895B2 (ja) * 2021-04-21 2025-05-16 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレイテッド 抗ヒト免疫グロブリン抗体を使用する抗微生物血清学的アッセイのための組成物、キット、および方法
CN115902235A (zh) * 2021-09-30 2023-04-04 长沙都正医学检验有限责任公司 利妥昔生物类似药双抗夹心elisa定量试剂盒及其应用
WO2023081898A1 (en) * 2021-11-08 2023-05-11 Alector Llc Soluble cd33 as a biomarker for anti-cd33 efficacy

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154598B (nl) 1970-11-10 1977-09-15 Organon Nv Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking.
US3817837A (en) 1971-05-14 1974-06-18 Syva Corp Enzyme amplification assay
US3939350A (en) 1974-04-29 1976-02-17 Board Of Trustees Of The Leland Stanford Junior University Fluorescent immunoassay employing total reflection for activation
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4277437A (en) 1978-04-05 1981-07-07 Syva Company Kit for carrying out chemically induced fluorescence immunoassay
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4366241A (en) 1980-08-07 1982-12-28 Syva Company Concentrating zone method in heterogeneous immunoassays
US4957939A (en) 1981-07-24 1990-09-18 Schering Aktiengesellschaft Sterile pharmaceutical compositions of gadolinium chelates useful enhancing NMR imaging
US4472509A (en) 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4938948A (en) 1985-10-07 1990-07-03 Cetus Corporation Method for imaging breast tumors using labeled monoclonal anti-human breast cancer antibodies
US5426029A (en) * 1986-03-31 1995-06-20 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using leukocyte surface antigens
US5824311A (en) 1987-11-30 1998-10-20 Trustees Of The University Of Pennsylvania Treatment of tumors with monoclonal antibodies against oncogene antigens
US5059522A (en) 1988-08-18 1991-10-22 Wayne Lawrence G Intrinsic enzyme dot blot immunoassay or indentification of microorganisms
US5227159A (en) 1989-01-31 1993-07-13 Miller Richard A Anti-idiotype antibodies reactive with shared idiotopes expressed by B cell lymphomas and autoantibodies
AU661816B2 (en) 1989-11-03 1995-08-10 Cancervax, Corp. Urinary tumor associated antigen, antigenic subunits uses and methods of detection
JPH049249A (ja) 1990-04-27 1992-01-14 Kusuda:Kk 塗型剤吹き付け機
US5726064A (en) 1990-11-22 1998-03-10 Applied Research Systems Ars Holding Nv Method of assay having calibration within the assay
US5234816A (en) 1991-07-12 1993-08-10 Becton, Dickinson And Company Method for the classification and monitoring of leukemias
US5525461A (en) * 1991-11-01 1996-06-11 T Cell Diagnostics, Inc. Therapeutic and diagnostic methods using total leukocyte surface antigens
US5597735A (en) 1992-05-11 1997-01-28 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Health And Welfare Glycolipids for serodiagnosis of tuberculosis and leprosy
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
DE69303494T2 (de) * 1992-11-13 1997-01-16 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörper gegen menschlichen b lymphozyt beschränkter differenzierung antigen für die behandlung von b-zell-lymphoma
US5801029A (en) 1993-02-16 1998-09-01 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
US5801005A (en) 1993-03-17 1998-09-01 University Of Washington Immune reactivity to HER-2/neu protein for diagnosis of malignancies in which the HER-2/neu oncogene is associated
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5667981A (en) 1994-05-13 1997-09-16 Childrens Hospital Of Los Angeles Diagnostics and treatments for cancers expressing tyrosine phosphorylated CRKL protein
GB9506466D0 (en) 1994-08-26 1995-05-17 Prolifix Ltd Cell cycle regulated repressor and dna element
US5739169A (en) 1996-05-31 1998-04-14 Procept, Incorporated Aromatic compounds for inhibiting immune response
CN1231761C (zh) * 1998-12-23 2005-12-14 梅德塞克股份有限公司 一种检测装置及鉴定分子的方法
ATE443259T1 (de) * 2001-09-20 2009-10-15 Univ Texas Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper- komplexe mit elisa-tests

Also Published As

Publication number Publication date
JP4424987B2 (ja) 2010-03-03
DE60233744D1 (de) 2009-10-29
WO2003024993A2 (en) 2003-03-27
JP2009075139A (ja) 2009-04-09
US7943332B2 (en) 2011-05-17
US20140335549A1 (en) 2014-11-13
WO2003024993A3 (en) 2003-10-16
EP1438583A4 (de) 2006-05-17
US20030068664A1 (en) 2003-04-10
HK1068411A1 (en) 2005-04-29
EP2131198A2 (de) 2009-12-09
JP2012198232A (ja) 2012-10-18
US10018638B2 (en) 2018-07-10
US20160069902A1 (en) 2016-03-10
EP1438583A2 (de) 2004-07-21
US9157916B2 (en) 2015-10-13
US7718387B2 (en) 2010-05-18
US8114618B2 (en) 2012-02-14
US8232068B2 (en) 2012-07-31
JP5264522B2 (ja) 2013-08-14
EP1438583B1 (de) 2009-09-16
AU2002327037A1 (en) 2003-04-01
US20140011215A1 (en) 2014-01-09
US8501423B2 (en) 2013-08-06
US20120107846A1 (en) 2012-05-03
JP5781014B2 (ja) 2015-09-16
US20100221761A1 (en) 2010-09-02
US20130004977A1 (en) 2013-01-03
US20180045736A1 (en) 2018-02-15
EP2131198B1 (de) 2013-03-27
JP2014089213A (ja) 2014-05-15
US8790882B2 (en) 2014-07-29
EP2131198A3 (de) 2010-07-07
US20110236994A1 (en) 2011-09-29
JP2005533236A (ja) 2005-11-04
US20190041399A1 (en) 2019-02-07

Similar Documents

Publication Publication Date Title
DE60233744D1 (de) Bestimmung der zirkulierenden therapeutischen antikörper, antigene sowie antigen-antikörper-komplexe mit elisa-tests
Ahn et al. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood
EA200500643A1 (ru) Способ неконкурентного иммуноанализа для определения малых аналитов
DK1139101T3 (da) Immunobestemmelse for C-reaktivt protein
JP2023017841A5 (de)
DK1565489T3 (da) Internaliserende antistoffer specifikke for RAAG10-celleoverflademålet
DK1350105T3 (da) Immunoanalyser for enti-HCV-antistoffer
EP1585966A4 (de) VERFAHREN ZUR IDENTIFIZIERUNG VON AUF DIE BEHANDLUNG MIT ANTI-ErbB2-ANTIK RPERN REAGIERENDEN TUMOREN
FI20030652A0 (fi) Parannettu immunomääritys
ATE554390T1 (de) Verfahren zur gewinnung von antikörpern
RU2001132335A (ru) Способ оценки наличия риска пептической язвы, включающий в себя этапы количественного определения концентрации пепсиногена i (pgi) и гастрин-17 в образце сыворотки
DK1167389T3 (da) Antistoffer mod SEMP1-proteinet, fremgangsmåde til fremstilling heraf samt anvendelse deraf
ATE519108T1 (de) Detektion von analyten in fäkalproben
ATE78601T1 (de) Test fuer menschlichen brustkrebs.
EP1245957A3 (de) Methode zur Konzentrationsbestimmung von Ceruloplasmin in einem Blutflecken mittels enzymgekoppeltem Immunosorbent-Assay oder mittels dissoziationsverstärktem, zeitaufgelöstem Immunofluoreszenzassay, sowie Kit zum Auffinden der Wilson-Krankheit und Diagnosemethode für letztere
CN101088010B (zh) 用于测定抗原的试剂以及抗原的测定方法
WO2001075449A1 (fr) Technique d'investigation du cancer par epreuve biologique d'un autoanticorps contre mdm2 et reactif
EP1059533A4 (de) Methode zum immunologischen nachweis des anti-hm1.24 antikörpers
EP1308730A4 (de) Verfahren zum nachweis oder zum bestimmen von hbv
ATE481644T1 (de) Prognose des verlaufs einer krebserkrankung
EP1347298A3 (de) Immunologisches Verfahren, Teststreifen und Vorrichtung
DK0991945T3 (da) Fremgangsmåde til identifikation af tumor-antigener med antistoffer i serum
WO2002090989A3 (de) Verfahren zum nachweis von blutzell-antigenen und gegen diese gerichtete antikörper
WO2003101176A3 (en) Method, composition and kit for antigenic binding of norwalk-like viruses
JP2009517667A (ja) サンプル中の被検体（抗原）および該被検体を標的とする治療用抗体を同時に免疫化学的に測定するためのイムノアッセイ（リカバリー・イムノアッセイ（ＲｅｃｏｖｅｒｙＩｍｍｕｎｏａｓｓａｙ））

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties